Heteropolysaccharides from S. cerevisiae show anti-adhesive properties against E. coli associated with Crohn's disease

Sivignon, Adeline; Yu, Shin‐Yi; Ballet, Nathalie; Vandekerckove, Pascal; Barnich, Nicolas; Guérardel, Yann

doi:10.1016/j.carbpol.2021.118415

Cited by 10 publications

(10 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S. cerevisiae var. boulardii sticks to the surface of pathogenic bacteria and reduces its multiplication and growth by accelerating bacterial excretion via the stools [ 68 ]. S. cerevisiae var.…”

Section: Clinical Significance Of S Cerevisiae Var...mentioning

confidence: 99%

Probiotic Yeast Saccharomyces: Back to Nature to Improve Human Health

Abid¹,

Waseem

Ali

et al. 2022

JoF

View full text Add to dashboard Cite

Saccharomyces cerevisiae var. boulardii is best known for its treatment efficacy against different gastrointestinal diseases. This probiotic yeast can significantly protect the normal microbiota of the human gut and inhibit the pathogenicity of different diarrheal infections. Several clinical investigations have declared S. cerevisiae var. boulardii a biotherapeutic agent due to its antibacterial, antiviral, anti-carcinogenic, antioxidant, anti-inflammatory and immune-modulatory properties. Oral or intramuscular administration of S. cerevisiae var. boulardii can remarkably induce health-promoting effects in the host body. Different intrinsic and extrinsic factors are responsible for its efficacy against acute and chronic gut-associated diseases. This review will discuss the clinical and beneficial effects of S. cerevisiae var. boulardii in the treatment and prevention of different metabolic diseases and highlight some of its health-promising properties. This review article will provide fundamental insights for new avenues in the fields of biotherapeutics, antimicrobial resistance and one health.

show abstract

Section: Clinical Significance Of S Cerevisiae Var...mentioning

confidence: 99%

Probiotic Yeast Saccharomyces: Back to Nature to Improve Human Health

Abid¹,

Waseem

Ali

et al. 2022

JoF

View full text Add to dashboard Cite

show abstract

“…In patients with active UC, reduced levels of chromosomal associated protein-D3 (CAP-D3) are thought to be critical for the reduced autophagy capacity and inhibited intracellular bacterial clearance. AIEC may participate in the regulation of CAP-D3 expression-related amino acid transporters[ 98 ].…”

Section: Aiec In Ucmentioning

confidence: 99%

Role of adherent invasive Escherichia coli in pathogenesis of inflammatory bowel disease

Duan¹,

Dai²,

Wu³

2022

World J Clin Cases

View full text Add to dashboard Cite

Gut microbiota imbalances play an important role in inflammatory bowel disease (IBD), but no single pathogenic microorganism critical to IBD that is specific to the IBD terminal ileum mucosa or can invade intestinal epithelial cells has been found. Invasive Escherichia coli ( E. coli) adhesion to macrophages is considered to be closely related to the pathogenesis of inflammatory bowel disease. Further study of the specific biological characteristics of adherent invasive E. coli (AIEC) may contribute to a further understanding of IBD pathogenesis. This review explores the relationship between AIEC and the intestinal immune system, discusses the prevalence and relevance of AIEC in Crohn's disease and ulcerative colitis patients, and describes the relationship between AIEC and the disease site, activity, and postoperative recurrence. Finally, we highlight potential therapeutic strategies to attenuate AIEC colonization in the intestinal mucosa, including the use of phage therapy, antibiotics, and anti-adhesion molecules. These strategies may open up new avenues for the prevention and treatment of IBD in the future.

show abstract

“…Furthermore, this model has highlighted in preclinical studies the efficacy of various anti-AIEC strategies, i.e. phage cocktail (EcoActive), various synthetic molecules based on mannose to block the interaction of FimH with CEACAM6, or yeast probiotics such as Saccharomyces cerevisiae (whole yeast or yeast extracts) to prevent the implantation of, or to eliminate, AIEC bacteria from the gut ( Galtier et al, 2017 ; Sivignon et al, 2015a , b , 2021 ). However, the limitation of this model relies on the fact that CEACAM6 expression is mainly located in the colon, whereas it remains very low in the small intestine.…”

Section: Discussionmentioning

confidence: 99%

“…Based on these studies, many AIEC-targeting strategies are currently under investigation in preclinical models and in clinical trials to limit AIEC blooming and invasion of ileal mucosa. For example, the efficacy of antibiotics (TEOREM, NCT02620007) or phagotherapy ( Galtier et al, 2017 ) (EcoActive, NCT03808103) to kill AIEC, or FimH antagonists ( Sivignon et al, 2015b ) (Sibofimloc, NCT03943446) and yeast probiotics ( Sivignon et al, 2015a , 2021 ) to decrease AIEC gut colonization, are currently under study. However, a well-established and validated preclinical model closely mimicking AIEC-induced CD pathogenesis is required to validate new therapeutic agents targeting AIEC bacteria.…”

Section: Introductionmentioning

confidence: 99%

“…The mouse genome lacks a human CEACAM6 gene orthologue, making it difficult to reproduce the AIEC–CEACAM6 interaction in vivo . In previous studies, we used the humanized carcinoembryonic antigen bacterial artificial chromosome 10 (CEABAC10) mouse model, in which we showed that AIEC bacteria are able to colonize the colonic mucosa of mice in a CEACAM6/FimH-dependent manner and to induce an inflammatory response ( Chan and Stanners, 2004 ; Carvalho et al, 2009 ; Lucchini et al, 2021 ; Sivignon et al, 2021 ). CEABAC10 mice carry a transgene encoding four genes of the CEACAM family members, including the CEACAM6 gene.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An adherent-invasive Escherichia coli-colonized mouse model to evaluate microbiota-targeting strategies in Crohn's disease

Sivignon

Chervy

Chevarin

et al. 2022

Disease Models &Amp; Mechanisms

Self Cite

View full text Add to dashboard Cite

Adherent-Invasive Escherichia coli (AIEC) was investigated for its involvement in the induction/chronicity of intestinal inflammation in Crohn's disease (CD). AIEC gut establishment is favoured by overexpression of the glycoprotein CEACAM6 in the ileal epithelium. We generated a transgenic mouse model named ‘Vill-hCC6’, in which the human CEACAM6 gene was under the control of the villin promoter, conditioning expression in the small intestine. We demonstrated that CEACAM6 is strongly expressed in the small intestine mucosa and is correlated with numerous glycosylations displayed at the brush border of enterocytes. In vitro, the AIEC-enterocyte interaction is enhanced by CEACAM6 expression and necessitates the presence of the bacterial adhesive factor FimH. Finally, AIEC bacteria preferentially persist in a FimH-dependent manner in the ileal mucosa of Vill-hCC6 mice compared to wild-type mice. This preclinical model opens new perspectives in the mechanistic study of the AIEC pathobiont and represents a valuable tool to evaluate the efficacy of new strategies to eliminate AIEC implanted in the ileal mucosa, such as phages, inhibitory and/or anti-virulence molecules, or CRISPR-based strategies targeting virulence or fitness factors of AIEC bacteria.

show abstract

Heteropolysaccharides from S. cerevisiae show anti-adhesive properties against E. coli associated with Crohn's disease

Cited by 10 publications

References 51 publications

Probiotic Yeast Saccharomyces: Back to Nature to Improve Human Health

Probiotic Yeast Saccharomyces: Back to Nature to Improve Human Health

Role of adherent invasive Escherichia coli in pathogenesis of inflammatory bowel disease

An adherent-invasive Escherichia coli-colonized mouse model to evaluate microbiota-targeting strategies in Crohn's disease

Contact Info

Product

Resources

About